1 The most recent
assessments were analyzed.
2 r density and anthocyanin/polyphenol content, while flavour
assessments were associated to titratable acidity and sugar-t
3 Diagnostic
assessments were blinded to mass spectrometry results.
4 equent development of mycelium and/or sporulation; fifthly,
assessments were carried out over a range of water-activity v
5 one, two, three, four, and five Coma Recovery Scale-Revised
assessments were compared with a reference diagnosis (ie, the
6 Symptom and quality of life questionnaires and cognitive
assessments were completed at both visits (n = 33).
7 The planned
assessments were completed by 76 children with konzo and 82 c
8 Assessments were completed by independent evaluators masked t
9 Neurodevelopmental
assessments were completed from 2010 to 2016.
10 Follow-up
assessments were completed on 16 January 2016.
11 Daily delirium
assessments were completed using the Preschool Confusion Asse
12 Sixty-four patients were enrolled and 214
assessments were conducted and included in data analysis.
13 Safety
assessments were conducted monthly.
14 Assessments were conducted pre-treatment (baseline) and after
15 review selection, data extraction and analysis, and quality
assessments were conducted using methods recommended by The C
16 Patients and Methods Cardiac marker
assessments were coupled with LVEF measurements at different
17 dent factors associated with HRQOL scores and missing HRQOL
assessments were determined using multivariable regression.
18 ssessment took place 6-12 weeks after deployment; follow-up
assessments were done 10-24 months later.
19 Assessments were done at baseline (before randomisation), aft
20 Assessments were done at baseline, 12 weeks, and 24 weeks, by
21 Assessments were done at study entry, 12 months, and 24 month
22 Efficacy
assessments were done in all randomly assigned patients (the
23 At each visit, clinical and laboratory (including HIV)
assessments were done.
24 Data were analyzed using intention-to-treat analysis, and
assessments were double-blinded through the primary outcome.
25 Patients with missing marker
assessments were excluded, resulting in 452 evaluable patient
26 between the emerging science and traditional chemical risk
assessments were explored, and approaches for bridging the ga
27 The dates of the data developmental
assessments were February 23, 2012, to April 8, 2016.
28 Safety
assessments were hospital admissions for the first 90 days an
29 Clinical outcome
assessments were made at the end of treatment, test of cure,
30 The
assessments were made before randomization and 6 and 12 month
31 Psychosocial
assessments were made in 75% (1234) of all episodes.
32 To help fill this knowledge gap, electrophysiological
assessments were made of mPFC pyramidal neurons (PN) from adu
33 Presurgical and postsurgical neuropsychological
assessments were obtained in 10 of 21 patients.
34 Clinical and laboratory
assessments were performed at 4, 8, 24, 48, and 72 hours and
35 Clinical
assessments were performed at baseline, after the interventio
36 Detailed neuropsychological and neuroendocrine
assessments were performed at preradiotherapy baseline, at 6
37 Assessments were performed at various time points for evaluat
38 Metabolic
assessments were performed before and after fructose restrict
39 Assessments were performed by an international multidisciplin
40 Clinical and laboratory
assessments were performed every 6 weeks.
41 Structured
assessments were performed preoperatively, 1 and 4 days after
42 Baseline and postintervention
assessments were performed using questionnaire, survey, and f
43 Neuropathologic
assessments were performed with investigators masked to clini
44 Detailed longitudinal motor and cognitive
assessments were performed with patients in the on state.
45 Mean costs of psychosocial
assessments were pound228 for adults and pound392 for individ
46 Mammogram indication and
assessments were prospectively collected for women undergoing
47 Vision
assessments were scheduled at 1, 2, 3, 6, 9, and 12 months po
48 The 2
assessments were separated by a 6-month washout period.
49 1 g/kg body weight) were established and lung tumorigenesis
assessments were taken after 15 weeks latency period.
50 The neuropsychological
assessments were the Kaufman Assessment Battery for Children,